All News
Filter News
Found 2,509 articles
-
Casebia Therapeutics Appoints Amy Jennings to Head Its Regulatory Affairs
5/30/2018
Casebia Therapeutics, a biopharmaceutical company dedicated to the creation of life-transforming therapeutics through gene-editing technology, has appointed Amy Jennings, Ph.D., as its head of Regulatory Affairs.
-
Feldan Therapeutics awarded US Patent for the second generation of its Feldan Shuttle platform
5/29/2018
Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform.
-
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
5/21/2018
MaxCyte, the global cell-based medicines and life sciences company, today announced that Linghong Li, PhD, Director, Cell Engineering, presented pre-clinical data at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Chicago on Friday, May 18, 2018, in which MaxCyte's non-viral cell engineering technology was used for CRISPR-mediated gene-correction of a mutation within the hemoglobin gene of cells from a sickle cell disease (SCD) patient.
-
Accent Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $40 million Series A financing. Accent will focus on the fairly new area of epitranscriptomics.
-
MilliporeSigma to Use Genome Editing in Study of Gut Bacteria to Benefit Malnourished Children
5/16/2018
Collaboration with Washington University on gut bacteria research could lead to diagnostics, treatment for malnourished children
-
With $87 Million in Hand, Beam Therapeutics Launches to Fight Disease with CRISPR Base Editing Te...
5/14/2018
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners. -
Beam Therapeutics Founded by Gene Editing Pioneers to Create Precision Genetic Medicines with Base Editing
5/14/2018
Beam Therapeutics announced today that it is launching to develop precision genetic medicines
-
Beam Therapeutics Launched to Develop Harvard Base Editing Technology toward Precision Genetic Medicines
5/14/2018
Harvard innovations enable the correction of single-base mutations in DNA with unprecedented precision and efficiency
-
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
-
Genome Surgery for Eye Disease Moves Closer to Reality
5/11/2018
Study published in the journal of the American Academy of Ophthalmology shows that a CRISPR-based treatment can restore retinal function in mice
-
Tango Therapeutics Bolsters Expertise in Oncology Translational Research and Clinical Pharmacology with Leadership Expansion
5/10/2018
Alan Huang, Ph.D. appointed chief scientific officer
-
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer
5/3/2018
Caribou Biosciences, Inc. announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer.
-
Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.
-
ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to Evotec
5/2/2018
ERS Genomics announced a patent license agreement with Hamburg-based Evotec AG, which gains non-exclusive access to the Company’s CRISPR/Cas9 patents to expand their research services offering.
-
Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics
5/2/2018
Evotec AG announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited.
-
Free Research Reports on These Biotech Stocks -- Exelixis, INSYS Therapeutics, Intellia Therapeutics, and Intercept Pharma
5/2/2018
WallStEquities.com is offering reports on EXEL, INSY, NTLA, and ICPT which can be accessed for free by signing up to www.wallstequities.com/registration.
-
IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
5/2/2018
IONTAS Limited and Ten Therapeutics Limitedannounced that they have entered into a strategic collaboration.
-
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
5/2/2018
Refuge Biotechnologies, Inc. announced the closing of a $25 million Series B investment round.